WARREN, N.J., June 12, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it will participate on a panel, titled Emerging Landscape of Treatment Options in PAH, at the JMP Securities Life Sciences Conference on Wednesday, June 20, 2018, in New York City. The conference is taking place June 20-21, 2018, at The St. Regis New York.
Bellerophon Presentation Details
Title: Emerging Landscape of Treatment Options in PAH
Date: Wednesday, June 20, 2018
Time: 9:00am-10:00am Eastern Time
Location: The St. Regis New York, Library Room
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. The first is for the treatment of PAH, for which the Company has commenced Phase 3 clinical trials. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third candidate is for the treatment of pulmonary hypertension associated with Interstitial Lung Disease (PH-ILD), both of which are in Phase 2 development. For more information, please visit www.bellerophon.com.
Fabian Tenenbaum, Chief Executive Officer
Bellerophon Therapeutics, Inc.